Key Drivers
- Strong liquidity
- High gross margins
- Quarterly volatility
AIAI Summary
BioMarin has shifted from a single‑product growth story to an execution‑dependent consolidator where VOXZOGO‑driven cash generation and high gross margins support opportunistic M&A, but investors should hold/watch pending pivotal readouts, early Amicus integration proof points, and stabilization of VOXZOGO order timing because further clinical or integration setbacks would sharply compress its premium valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High gross margins
- •Quarterly volatility
BioMarin exhibits strong liquidity and full-year cash generation with healthy margins and low leverage, but heavy operating spend drove a quarterly loss and the stock trades at a premium.
Price Behavior
Key Price Behavior Insights:
- •Downward trend
- •Oversold momentum
- •Resistance cluster
BMRN has slipped from a mid‑February peak into a lower trading band and sits below its last‑month average, but a mid‑20s RSI suggests oversold conditions that could prompt a short relief bounce.
Drop from mid‑February peak into a lower trading band by 2026-03-20
Sentiment & News
Key News Insights:
- •Strong commercial
- •Safety setback
- •M&A activity
BioMarin beat Q4 expectations and grew 2025 revenue ~13% while announcing a definitive Amicus acquisition, withdrawing Roctavian, gaining FDA approval for PALYNZIQ in adolescents, facing a halted bone‑therapy trial after hip safety events, and seeing notable institutional ownership shifts.
Mixed signals—commercial and regulatory wins support near‑term revenue and valuation, but the Roctavian withdrawal and halted trial heighten pipeline risk and could temper upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings